Dr. Jiang Biao serves as the Chief Scientist at Landcent and holds one of the highest positions at Shanghai Institute of Organic Chemistry which comes under the China Academy of Sciences, the national think tank of China. He also serves as the Director of SARI (Shanghai Advanced Research Institute) and leads the CAS Innovation Cooperation Center for the ASEAN countries.

Dr. Ole is referred to as the father of treated bednets and was instrumental in inventing the long-lasting insecticide-treated bednets that are used worldwide in preventing vector-borne diseases. He is a shareholder at Landcent and plays an active role in product development, manufacturing scalability and most importantly, overseeing the field trials. Dr. Ole has published several theoretical and practical articles related to vector control and is a member of the Society for Vector Ecology, American Chemical Society, Entomological Society of America and more.

Dr. Peter Atadja is the Chief Scientific Officer at Landcent and full Professor of Biomedical Sciences at the University of Health and Allied Sciences (UHAS) Ghana. He has about 25 years' experience in the Pharmaceutical Industry, including being part of the founding and leadership team of Novartis' 3rd largest global R&D centre located in Shanghai, China, where he led the discovery and clinical translation of several first and best-in-class drug candidates. More recently, he was co-founder and Chief Scientific Officer of K36 Therapeutics, a clinical phase biopharmaceutical company in Cambridge, MA, USA.

Dr. Svetlana Randle is a seasoned senior researcher with extensive R&D expertise, particularly in Vector control. Formerly associated with the Innovative Vector Control Consortium, a prominent Partnership in the development program funded by the Bill & Melinda Gates Foundation, she also served as a consultant to the WHO pre-qualification team, offering technical insights for product reviews. With over 10 years at Unilever, she held roles as a scientist and later as a Team Leader. Dr. Randle earned her PhD and completed post-doctoral work at the University of Manchester.

Dr. Mei Wang is the founder and CEO of SU Biomedicine and the founder of Leiden University – European Center for Chinese Medicine and Natural Compounds (LUECCM). She has more than 160 publications in international double-refereed journals and has worked in cooperation with leading universities including Cambridge, Oxford, Yale and Regensburg University. In 2020, she obtained the 2nd prize for International Contribution Award of Traditional Chinese Medicine- Science and Technology Progress Award WFCMS.

Kailash Raghuwanshi has been with Landcent for six years as a Board member and, for the past two years, as Director, playing a key role in its global expansion. He currently leads strategic initiatives, including philanthropic partnerships like a Gates Foundation-funded project for exploring ovel compounds from traditional Chinese medicine. He actively involved in Southeast Asia’s early-stage venture ecosystem and with landcent delved into antimicrobial new materials. he began his career at New York State Hospital and graduated from Stony Brook University, New York.